Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

Raphael J. Landovitz, Deborah Donnell, Meredith E. Clement et al. · New England Journal of Medicine · 2021 · 853 citations · Full text

Public Health, Infectious Diseases, Pharmacotherapy +16

Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial

Sinéad Delany‐Moretlwe, James P. Hughes, Peter Bock et al. · The Lancet · 2022 · 540 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women

Linda‐Gail Bekker, Moupali Das, Quarraisha Abdool Karim et al. · New England Journal of Medicine · 2024 · 427 citations

Public Health, Pharmacotherapy, Preventive Medicine +17

Clinical targeting of HIV capsid protein with a long-acting small molecule

John O. Link, Martin S. Rhee, Winston C. Tse et al. · Nature · 2020 · 421 citations · Full text

Pharmacy, Molecular Biology, Pharmaceutics +12

Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons

Colleen F. Kelley, Maribel Acevedo-Quiñones, Allison L. Agwu et al. · New England Journal of Medicine · 2024 · 229 citations

Public Health, Pharmacology, Pharmacotherapy +17